ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

IPCA LABORATORIES- New Opportunities

group is demanding a withdrawal of contingent liabilities of Rs 113 crore by the state government and waiver of interest by banks and financial institutions together amounting to Rs 269 crore, SPIC wants a one-time interest waiver of Rs 170 crore and a derating of the plant capacity by nearly half in order to avail of a higher issue price from the central government, IPCA LABORATORIES New Opportunities Incorporated in 1949, IPCA Laboratories has grown through a strategy of expansion and acquisitions. It acquired the Kandla tabletting unit from Hoechst (India) in 1992-93, the US FDA approved Indore unit from BDH Pharmaceuticals (an erstwhile associate of E Merck) and another export-oriented unit for psyllium husk at Sidhpur, The company's bulk drugs/ intermediates facilities are situated at Ratlam and Indore in Madhya Pradesh, while its formulation plants are based in Kandivli (Mumbai), Ratlam, Kandla Free Trade Zone (Gujarat) and Athal (Silvassa).

Dear reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here


(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top